# US 2013/0251699 A1 · Designer ubiquitin ligases for regulation of intracellular pathogenic proteins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0251699 A1
- Document ID: US20130251699A1
- Status: Published application
- Kind: A1
- Application number: 13/726,915
- Filed: 2012-12-26
- Published: 2013-09-26
- Earliest claimed: 2008-06-10
- Assignees: Synaptic Research, LLC
- Applicants: Synaptic Research, LLC
- Inventors: George A. Oyler; Yien Che Tsai
- Web page: https://patentgrep.com/patent/US20130251699A1

## CPC

- C12N 9/93: {Ligases (6)}
- A61K 38/4886: {Metalloendopeptidases (3.4.24), e.g. collagenase}
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to a designer or recombinant ubiquitin ligase molecule that includes a toxin binding domain that is specific for a toxin active fragment, wherein the toxin active fragment is an enzymatically active fragment of one or more toxins or toxin serotypes; and an E3-ligase domain that comprises an E3-ligase or polypeptide that facilitates E2-mediated ubiquitination of the toxin active fragment. In an embodiment, the composition further includes a delivery system that allow the designer ubiquitin ligase to enter the cell. The present invention further includes methods for treating an individual intoxicated with a toxin by administering the designer ubiquitin ligase of the present invention.

## Claims

### Claim 1

A method of degrading or inhibiting one or more botulinum neurotoxin (BoNT) serotypes that have intoxicated one or more cells, wherein the method comprises contacting an amount of an isolated recombinant ubiquitin ligase molecule with the intoxicated cells, wherein the isolated recombinant ubiquitin ligase molecule comprises:
a. a non-cleavable SNAP-25 domain that binds to an enzymatically active fragment of a BoNT, wherein the non-cleavable SNAP-25 domain consists essentially of an amino acid sequence selected from the group consisting of:
i. an amino acid sequence encoded by a nucleic acid having greater than or equal to about 90% identity with nucleic acid bases 1 to 618 of SEQ ID NO: 11 or 13;
ii. an amino acid sequence encoded by a nucleic acid having greater than or equal to about 90% identity with a complement of nucleic acid bases 1 to 618 of SEQ ID NO: 11 or 13;
iii. an amino acid sequence encoded by a nucleic acid sequence of a nucleic acid molecule that hybridizes under high stringency conditions to nucleic acid bases 1 to 618 of SEQ ID NO: 11 or 13, or to a complement of nucleic acid bases 1 to 618 of SEQ ID NO: 11 or 13, wherein said high stringency conditions comprise a temperature between about 40° C. and about 60° C., an SSC concentration between about 1× and about 10×, and a reaction time between about 30 seconds and about 36 hours; and
iv. an amino acid sequence having greater than or equal to about 90% similarity to a sequence set forth in amino acid bases 1 to 206 of SEQ ID NO: 12 or 14; and
b. an E3-ligase domain that comprises an E3-ligase or polypeptide that facilitates E2-mediated ubiquitination of the enzymatically active fragment of a BoNT,
wherein the isolated recombinant ubiquitin ligase molecule degrades or inhibits at least one BoNT serotype.

### Claim 2 (depends on 1)

The method of claim 1, wherein the E3-ligase domain consists essentially of an amino acid sequence selected from the group consisting of:
i. an amino acid sequence encoded by a nucleic acid having greater than or equal to about 90% identity with nucleic acid bases from 619 to 1029 of SEQ ID NO: 11 or 13;
ii. an amino acid sequence encoded by a nucleic acid having greater than or equal to about 90% identity with a complement of nucleic acid bases from 619 to 1029 of SEQ ID NO: 11 or 13;
iii. an amino acid sequence encoded by a nucleic acid sequence of a nucleic acid molecule that hybridizes under high stringency conditions to nucleic acid bases from 619 to 1029 of SEQ ID NO: 11 or 13, or to a complement of nucleic acid bases from 619 to 1029 of SEQ ID NO: 11 or 13, wherein said high stringency conditions comprise a temperature between about 40° C. and about 60° C., an SSC concentration between about 1× and about 10×, and a reaction time between about 30 seconds and about 36 hours; and
iv. an amino acid sequence having greater than or equal to about 90% similarity to a sequence set forth in amino acid bases 207 to 343 of SEQ ID NO: 12 or 14,
wherein the isolated recombinant ubiquitin ligase molecule degrades or inhibits at least one BoNT serotype.

### Claim 3 (depends on 2)

The method of claim 2, wherein the isolated recombinant ubiquitin ligase molecule further comprises a BoNT holotoxin, wherein the BoNT holotoxin comprises a light chain with a deletion, a heavy chain with a mutation, or both a light chain with a deletion and a heavy chain with a mutation, wherein the deletion, mutation, or both the deletion and the mutation render the BoNT holotoxin atoxic.

### Claim 4 (depends on 2)

The method of claim 2, wherein the isolated recombinant ubiquitin ligase molecule further comprises a translocation cellular binding domain or an N-terminus of a BoNT atoxic holotoxin.

### Claim 5 (depends on 1)

The method of claim 1, wherein the amount of the isolated recombinant ubiquitin ligase molecule ranges from about 1 nM to about 100 mM.

### Claim 6 (depends on 1)

The method of claim 1, wherein the isolated recombinant ubiquitin ligase molecule is contacted with the intoxicated cells for a time that ranges from about 1 minute to about 1 week.

### Claim 7

A method of treating an individual having one or more cells intoxicated with one or more BoNT serotypes, wherein the method comprises administering to the individual an amount of an isolated recombinant ubiquitin ligase molecule in a carrier, wherein the isolated recombinant ubiquitin ligase molecule comprises:
a. a non-cleavable SNAP-25 domain that binds to an enzymatically active fragment of a BoNT, wherein the non-cleavable SNAP-25 domain consists essentially of an amino acid sequence selected from the group consisting of:
i. an amino acid sequence encoded by a nucleic acid having greater than or equal to about 90% identity with nucleic acid bases 1 to 618 of SEQ ID NO: 11 or 13;
ii. an amino acid sequence encoded by a nucleic acid having greater than or equal to about 90% identity with a complement of nucleic acid bases 1 to 618 of SEQ ID NO: 11 or 13;
iii. an amino acid sequence encoded by a nucleic acid sequence of a nucleic acid molecule that hybridizes under high stringency conditions to nucleic acid bases 1 to 618 of SEQ ID NO: 11 or 13, or to a complement of nucleic acid bases 1 to 618 of SEQ ID NO: 11 or 13, wherein said high stringency conditions comprise a temperature between about 40° C. and about 60° C., an SSC concentration between about 1× and about 10×, and a reaction time between about 30 seconds and about 36 hours; and
iv. an amino acid sequence having greater than or equal to about 90% similarity to a sequence set forth in amino acid bases 1 to 206 of SEQ ID NO: 12 or 14; and
b. an E3-ligase domain that comprises an E3-ligase or polypeptide that facilitates E2-mediated ubiquitination of the enzymatically active fragment of a BoNT,
wherein one or more symptoms associated with BoNT intoxication are reduced or reversed.

### Claim 8 (depends on 7)

The method of claim 7, wherein the E3-ligase domain consists essentially of an amino acid sequence selected from the group consisting of:
i. an amino acid sequence encoded by a nucleic acid having greater than or equal to about 90% identity with nucleic acid bases from 619 to 1029 of SEQ ID NO: 11 or 13;
ii. an amino acid sequence encoded by a nucleic acid having greater than or equal to about 90% identity with a complement of nucleic acid bases from 619 to 1029 of SEQ ID NO: 11 or 13;
iii. an amino acid sequence encoded by a nucleic acid sequence of a nucleic acid molecule that hybridizes under high stringency conditions to nucleic acid bases from 619 to 1029 of SEQ ID NO: 11 or 13, or to a complement of nucleic acid bases from 619 to 1029 of SEQ ID NO: 11 or 13, wherein said high stringency conditions comprise a temperature between about 40° C. and about 60° C., an SSC concentration between about 1× and about 10×, and a reaction time between about 30 seconds and about 36 hours; and
iv. an amino acid sequence having greater than or equal to about 90% similarity to a sequence set forth in amino acid bases 207 to 343 of SEQ ID NO: 12 or 14,
wherein one or more symptoms associated with BoNT intoxication are reduced or reversed.

### Claim 9 (depends on 8)

The method of claim 8, wherein the isolated recombinant ubiquitin ligase molecule further comprises a BoNT holotoxin, wherein the BoNT holotoxin comprises a light chain with a deletion, a heavy chain with a mutation, or both a light chain with a deletion and a heavy chain with a mutation, wherein the deletion, mutation, or both the deletion and the mutation render the BoNT holotoxin atoxic.

### Claim 10 (depends on 8)

The method of claim 8, wherein the isolated recombinant ubiquitin ligase molecule further comprises a translocation cellular binding domain or an N-terminus of a BoNT atoxic holotoxin.

### Claim 11 (depends on 7)

The method of claim 7, wherein one or more symptoms associated with BoNT intoxication that are reduced or reversed include blurred vision, dry mouth, difficulty swallowing, difficulty speaking, paralysis, muscle weakness; respiratory failure, and decreased nerve conduction.

### Claim 12 (depends on 7)

The method of claim 7, wherein the amount of the isolated recombinant ubiquitin ligase molecule administered to the individual ranges from about 1 nanogram to about 5 grams.

### Claim 13 (depends on 12)

The method of claim 12, wherein the amount of the isolated recombinant ubiquitin ligase molecule is administered intravenously, parenterally, orally, nasally, by inhalation, by implant, by injection, or by suppository.

### Claim 14 (depends on 13)

The method of claim 13, wherein the amount of the isolated recombinant ubiquitin ligase molecule is administered once or periodically.

### Claim 15

An isolated nucleic acid molecule that encodes a recombinant ubiquitin ligase molecule, wherein recombinant ubiquitin ligase comprises:
a. a toxin binding domain that has an affinity for an enzymatically active fragment of one or more toxins or toxin serotypes, wherein the toxin binding domain comprises a non-cleavable SNAP-25 domain that is encoded by a nucleic acid molecule that consists essentially of a nucleic acid sequence selected from the group consisting of:
i. a nucleic acid sequence having greater than or equal to about 90% identity with nucleic acid bases 1 to 618 of SEQ ID NO: 11 or 13;
ii. a nucleic acid sequence complement having greater than or equal to about 90% identity with nucleic acid bases 1 to 618 of SEQ ID NO: 11 or 13;
iii. a nucleic acid molecule that hybridizes to nucleic acid bases 1 to 618 of SEQ ID NO: 11 or 13 under high stringency conditions, wherein said conditions comprise a temperature range between about 40° C. and about 60° C., an SSC concentration range between about 1× and about 10× and a reaction time range of between about 30 seconds and about 36 hours; and
iv. a nucleic acid sequence that encodes an amino acid sequence having greater than or equal to about 90% similarity to a sequence set forth in amino acid bases 1 to 206 of SEQ ID NO: 12 or 14; and
b. an E3-ligase domain that comprises an E3-ligase or polypeptide that facilitates E2-mediated ubiquitination of the toxin enzymatically active fragment, wherein the E3-ligase domain is encoded by a nucleic acid molecule that consists essentially of a nucleic acid sequence selected from the group consisting of:
i. a nucleic acid sequence having greater than or equal to about 90% identity with nucleic acid bases from 619 to 1029 of SEQ ID NO: 11 or 13;
ii. a nucleic acid sequence complement having greater than or equal to about 90% identity with nucleic acid bases from 619 to 1029 of SEQ ID NO: 11 or 13;
iii. a nucleic acid molecule that hybridizes to nucleic acid bases from 619 to 1029 of SEQ ID NO: 11 or 13 under high stringency conditions, wherein said conditions comprise a temperature range between about 40° C. and about 60° C., an SSC concentration range between about 1× and about 10× and a reaction time range of between about 30 seconds and about 36 hours; and
iv. a nucleic acid sequence that encodes an amino acid sequence having greater than or equal to about 90% similarity to a sequence set forth in amino acid bases 207 to 343 of SEQ ID NO: 12 or 14.

### Claim 16 (depends on 15)

The isolated nucleic acid molecule that encodes the recombinant ubiquitin ligase molecule of claim 15, wherein the non-cleavable SNAP-25 domain binds to the enzymatically active fragment of a botulinum neurotoxin (BoNT).

### Claim 17

An isolated nucleic acid molecule that encodes a recombinant ubiquitin ligase molecule, wherein recombinant ubiquitin ligase comprises:
a. a toxin binding domain that has an affinity for an enzymatically active fragment of one or more toxins or toxin serotypes, wherein the toxin binding domain comprises a non-cleavable SNAP-25 domain, wherein the non-cleavable SNAP-25 domain consists essentially of an amino acid sequence selected from the group consisting of:
i. an amino acid sequence encoded by a nucleic acid having greater than or equal to about 90% identity with nucleic acid bases 1 to 618 of SEQ ID NO: 11 or 13;
ii. an amino acid sequence encoded by a complement having greater than or equal to about 90% identity with of nucleic acid bases 1 to 618 of SEQ ID NO: 11 or 13;
iii. an amino acid sequence encoded by a nucleic acid molecule that hybridizes to nucleic acid bases 1 to 618 of SEQ ID NO: 11 or 13 under high stringency conditions, wherein said conditions comprise a temperature range between about 40° C. and about 60° C., an SSC concentration range between about 1× and about 10× and a reaction time range of between about 30 seconds and about 36 hours; and
iv. an amino acid sequence having greater than or equal to about 90% similarity to a sequence set forth in amino acid bases 1 to 206 of SEQ ID NO: 12 or 14; and
b. an E3-ligase domain that comprises an E3-ligase or polypeptide that facilitates E2-mediated ubiquitination of the toxin enzymatically active fragment, wherein the E3-ligase domain consists essentially of an amino acid sequence selected from the group consisting of:
i. an amino acid sequence encoded by a nucleic acid having greater than or equal to about 90% identity with nucleic acid bases from 619 to 1029 of SEQ ID NO: 11 or 13;
ii. an amino acid sequence encoded by a complement having greater than or equal to about 90% identity with nucleic acid bases from 619 to 1029 of SEQ ID NO: 11 or 13;
iii. an amino acid sequence encoded by a nucleic acid molecule that hybridizes to nucleic acid bases from 619 to 1029 of SEQ ID NO: 11 or 13 under high stringency conditions, wherein said conditions comprise a temperature range between about 40° C. and about 60° C., an SSC concentration range between about 1× and about 10× and a reaction time range of between about 30 seconds and about 36 hours; and
iv. an amino acid sequence having greater than or equal to about 90% similarity to a sequence set forth in amino acid bases 207 to 343 of SEQ ID NO: 12 or 14.

### Claim 18 (depends on 17)

The isolated nucleic acid molecule that encodes the recombinant ubiquitin ligase molecule of claim 17, wherein the serotypes comprise BoNT serotypes A, C, or E.

### Claim 19

An isolated nucleic acid molecule that encodes a recombinant ubiquitin ligase molecule, wherein the nucleic acid molecule consists essentially of a nucleic acid sequence selected from the group consisting of:
a. a nucleic acid sequence having greater than or equal to about 90% identity with SEQ ID NO: 11 or 13;
b. a nucleic acid sequence complement having greater than or equal to about 90% identity with of SEQ ID NO: 11 or 13;
c. a nucleic acid molecule that hybridizes to SEQ ID NO: 11 or 13 under high stringency conditions, wherein said conditions comprise a temperature range between about 40° C. and about 60° C., an SSC concentration range between about 1× and about 10× and a reaction time range of between about 30 seconds and about 36 hours; and
d. a nucleic acid sequence that encodes an amino acid sequence having greater than or equal to about 90% similarity to a sequence set forth in SEQ ID NO: 12 or 14
wherein the isolated recombinant ubiquitin ligase molecule comprises a non-cleavable SNAP-25 toxin binding domain that binds to the enzymatically active fragment of BoNT, and a RING E3-ligase domain that facilitates E2-mediated ubiquitination of the toxin enzymatically active fragment.

### Claim 20

An isolated nucleic acid molecule that encodes a recombinant ubiquitin ligase molecule, wherein recombinant ubiquitin ligase molecule is selected from the group consisting of:
e. an amino acid sequence encoded by a nucleic acid having greater than or equal to about 90% identity with SEQ ID NO: 11 or 13;
f. an amino acid sequence encoded by a complement having greater than or equal to about 90% identity with of SEQ ID NO: 11 or 13;
g. an amino acid sequence encoded by a nucleic acid that hybridizes to SEQ ID NO: 11 or 13 under high stringency conditions, wherein said conditions comprise a temperature range between about 40° C. and about 60° C., an SSC concentration range between about 1× and about 10× and a reaction time range of between about 30 seconds and about 36 hours; and
h. an amino acid sequence having greater than or equal to about 90% similarity to a sequence set forth in SEQ ID NO: 12 or 14
wherein the isolated recombinant ubiquitin ligase molecule comprises a non-cleavable SNAP-25 toxin binding domain that binds to the enzymatically active fragment of BoNT, and a RING E3-ligase domain that facilitates E2-mediated ubiquitination of the toxin enzymatically active fragment.
